Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study

Autor: Laurence Morin, Louis-Philippe Grenier, Nicolas Foucault, Éric Lévesque, François Fabi, Eve-Lyne Langlais, Alexandra Sebastianelli, Marianne Lavoie, Marc Lalancette, Marie Plante, Mahukpe Narcisse Ulrich Singbo, Vincent Castonguay

Publikováno v: Current Oncology, Vol 31, Iss 8, Pp 4624-4631 (2024)

Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these r

Externí odkaz: https://doaj.org/article/a676d5b9c983478eacedf9d38891e071

The neurophysiological brain-fingerprint of Parkinson’s diseaseResearch in context

Autor: Jason da Silva Castanheira, Alex I. Wiesman, Justine Y. Hansen, Bratislav Misic, Sylvain Baillet, John Breitner, Judes Poirier, Pierre Bellec, Véronique Bohbot, Mallar Chakravarty, Louis Collins, Pierre Etienne, Alan Evans, Serge Gauthier, Rick Hoge, Yasser Ituria-Medina, Gerhard Multhaup, Lisa-Marie Münter, Natasha Rajah, Pedro Rosa-Neto, Jean-Paul Soucy, Etienne Vachon-Presseau, Sylvia Villeneuve, Philippe Amouyel, Melissa Appleby, Nicholas Ashton, Daniel Auld, Gülebru Ayranci, Christophe Bedetti, Marie-Lise Beland, Kaj Blennow, Ann Brinkmalm Westman, Claudio Cuello, Mahsa Dadar, Leslie-Ann Daoust, Samir Das, Marina Dauar-Tedeschi, Louis De Beaumont, Doris Dea, Maxime Descoteaux, Marianne Dufour, Sarah Farzin, Fabiola Ferdinand, Vladimir Fonov, Julie Gonneaud, Justin Kat, Christina Kazazian, Anne Labonté, Marie-Elyse Lafaille-Magnan, Marc Lalancette, Jean-Charles Lambert, Jeannie-Marie Leoutsakos, Laura Mahar, Axel Mathieu, Melissa McSweeney, Pierre-François Meyer, Justin Miron, Jamie Near, Holly NewboldFox, Nathalie Nilsson, Pierre Orban, Cynthia Picard, Alexa Pichet Binette, Jean-Baptiste Poline, Sheida Rabipour, Alyssa Salaciak, Matthew Settimi, Sivaniya Subramaniapillai, Angela Tam, Christine Tardif, Louise Théroux, Jennifer Tremblay-Mercier, Stephanie Tullo, Irem Ulku, Isabelle Vallée, Henrik Zetterberg, Vasavan Nair, Jens Pruessner, Paul Aisen, Elena Anthal, Alan Barkun, Thomas Beaudry, Fatiha Benbouhoud, Jason Brandt, Leopoldina Carmo, Charles Edouard Carrier, Laksanun Cheewakriengkrai, Blandine Courcot, Doris Couture, Suzanne Craft, Christian Dansereau, Clément Debacker, René Desautels, Sylvie Dubuc, Guerda Duclair, Mark Eisenberg, Rana El-Khoury, Anne-Marie Faubert, David Fontaine, Josée Frappier, Joanne Frenette, Guylaine Gagné, Valérie Gervais, Renuka Giles, Renee Gordon, Clifford Jack, Benoit Jutras, Zaven Khachaturian, David Knopman, Penelope Kostopoulos, Félix Lapalme, Tanya Lee, Claude Lepage, Illana Leppert, Cécile Madjar, David Maillet, Jean-Robert Maltais, Sulantha Mathotaarachchi, Ginette Mayrand, Diane Michaud, Thomas Montine, John Morris, Véronique Pagé, Tharick Pascoal, Sandra Peillieux, Mirela Petkova, Galina Pogossova, Pierre Rioux, Mark Sager, Eunice Farah Saint-Fort, Mélissa Savard, Reisa Sperling, Shirin Tabrizi, Pierre Tariot, Eduard Teigner, Ronald Thomas, Paule-Joanne Toussaint, Miranda Tuwaig, Vinod Venugopalan, Sander Verfaillie, Jacob Vogel, Karen Wan, Seqian Wang, Elsa Yu, Isabelle Beaulieu-Boire, Pierre Blanchet, Sarah Bogard, Manon Bouchard, Sylvain Chouinard, Francesca Cicchetti, Martin Cloutier, Alain Dagher, Clotilde Degroot, Alex Desautels, Marie Hélène Dion, Janelle Drouin-Ouellet, Anne-Marie Dufresne, Nicolas Dupré, Antoine Duquette, Thomas Durcan, Lesley K. Fellows, Edward Fon, Jean-François Gagnon, Ziv Gan-Or, Angela Genge, Nicolas Jodoin, Jason Karamchandani, Anne-Louise Lafontaine, Mélanie Langlois, Etienne Leveille, Martin Lévesque, Calvin Melmed, Oury Monchi, Jacques Montplaisir, Michel Panisset, Martin Parent, Minh-Thy Pham-An, Ronald Postuma, Emmanuelle Pourcher, Trisha Rao, Jean Rivest, Guy Rouleau, Madeleine Sharp, Valérie Soland, Michael Sidel, Sonia Lai Wing Sun, Alexander Thiel, Paolo Vitali

Publikováno v: EBioMedicine, Vol 105, Iss , Pp 105201- (2024)

Summary: Background: Research in healthy young adults shows that characteristic patterns of brain activity define individual “brain-fingerprints” that are unique to each person. However, variability in these brain-fingerprints increases in indivi

Externí odkaz: https://doaj.org/article/53cebec840074e92a908d46662561dae

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease

Autor: Isabelle Laverdière, Chantal Guillemette, Ryad Tamouza, Pascale Loiseau, Regis Peffault de Latour, Marie Robin, Félix Couture, Alain Filion, Marc Lalancette, Alan Tourancheau, Dominique Charron, Gérard Socié, Éric Lévesque

Publikováno v: Haematologica, Vol 100, Iss 2 (2015)

Effective immunosuppression is mandatory to prevent graft-versus-host disease and to achieve a successful clinical outcome of hematopoietic stem cell transplantation. Here we tested whether germline single nucleotide polymorphisms in 20 candidate gen

Externí odkaz: https://doaj.org/article/33498813872146958067324981fd6169

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Autor: Bingshu E. Chen, Lois E. Shepherd, Harriet Richardson, Donna E. Reece, Christopher P. Venner, Bethany Monteith, Joe Pater, Rodger E. Tiedemann, Vishal Kukreti, Matthew C. Cheung, Jill Dudebout, Hope Yen, Marc Lalancette, Chai Phua, Max Sherry, Annette E. Hay, Engin Gul, Vincent Castonguay, Sita D. Bhella

Publikováno v: European Journal of Haematology. 107:333-342

Background The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020). The MYX.1 phase II trial showed that high-dose weekly carfilzomib, cyclophosphamide, and dexame

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadb8a625d7030a13a0045d62878aa6d
https://doi.org/10.1111/ejh.13671

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial

Autor: Sean Dolan, Max Sherry, Irwindeep Sandhu, Christine Chen, Arleigh McCurdy, Christopher P. Venner, Andrea Kew, Annette E. Hay, Martha L Louzada, Richard Leblanc, Tony Reiman, Gail T. McDonald, Marc Lalancette, Bingshu E. Chen, Andrew R. Belch, Engin Gul, Donna E. Reece, Bethany Monteith, Darrell White

Publikováno v: American journal of hematologyREFERENCES. 96(5)

The MCRN-003/CCTGMYX.1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient immunomodulator (IMiD)-free regimen in relapsed myeloma. Weekly carfilzomib (20/70 mg/m2 ), dexamethasone 4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e3e9be84a694dca075905c2a1a8cfb
https://pubmed.ncbi.nlm.nih.gov/33650179